A novel approach to immunoapheresis of C3a/C3 and proteomic identification of associates.
Complement factor C3a/C3
Electrophoresis
Immunoapheresis
Mass spectrometry
Monoclonal antibody
Proteomic analysis
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2019
2019
Historique:
received:
06
09
2019
accepted:
15
11
2019
entrez:
25
12
2019
pubmed:
25
12
2019
medline:
25
12
2019
Statut:
epublish
Résumé
Complement factor C3 represents the central component of the complement cascade and its activation split product C3a plays an important role in inflammation and disease. Many human disorders are linked to dysregulation of the complement system and alteration in interaction molecules. Therefore, various therapeutic approaches to act on the complement system have been initiated. Aiming to develop a tool to eliminate C3a/C3 from the circulation, in a first step a high affine murine monoclonal antibody (mAb) (3F7E2-mAb) was generated against complement factor C3 and selected for binding to the C3a region to serve as immunoaffinity reagent. Functional testing of the 3F7E2-mAb revealed an inhibition of Zymosan-induced cleavage of C3a from C3. Subsequently, a C3a/C3 specific 3F7E2-immunoaffinity column was developed and apheresis of C3a/C3 and associates was performed. Finally, a proteomic analysis was carried out for identification of apheresis products. C3a/C3 was liberated from the 3F7E2-column together with 278 proteins. C3a/C3 interaction specificity was validated by using a haptoglobin immunoaffinity column as control and biostatistic analysis revealed 39 true C3a/C3 interactants. A novel and functionally active mAb was developed against complement factor C3a/C3 and used in a specific immunoaffinity column that allows apheresis of C3a/C3 and associates and their identification by proteomic analysis. This methodological approach of developing specific antibodies that can be used as immunoaffinity reagents to design immunoaffinity columns for elimination and further identification of associated proteins could open new avenues for the development of tailored immunotherapy in various complement-mediated or autoimmune diseases.
Sections du résumé
BACKGROUND
BACKGROUND
Complement factor C3 represents the central component of the complement cascade and its activation split product C3a plays an important role in inflammation and disease. Many human disorders are linked to dysregulation of the complement system and alteration in interaction molecules. Therefore, various therapeutic approaches to act on the complement system have been initiated.
METHODS AND RESULTS
RESULTS
Aiming to develop a tool to eliminate C3a/C3 from the circulation, in a first step a high affine murine monoclonal antibody (mAb) (3F7E2-mAb) was generated against complement factor C3 and selected for binding to the C3a region to serve as immunoaffinity reagent. Functional testing of the 3F7E2-mAb revealed an inhibition of Zymosan-induced cleavage of C3a from C3. Subsequently, a C3a/C3 specific 3F7E2-immunoaffinity column was developed and apheresis of C3a/C3 and associates was performed. Finally, a proteomic analysis was carried out for identification of apheresis products. C3a/C3 was liberated from the 3F7E2-column together with 278 proteins. C3a/C3 interaction specificity was validated by using a haptoglobin immunoaffinity column as control and biostatistic analysis revealed 39 true C3a/C3 interactants.
CONCLUSION
CONCLUSIONS
A novel and functionally active mAb was developed against complement factor C3a/C3 and used in a specific immunoaffinity column that allows apheresis of C3a/C3 and associates and their identification by proteomic analysis. This methodological approach of developing specific antibodies that can be used as immunoaffinity reagents to design immunoaffinity columns for elimination and further identification of associated proteins could open new avenues for the development of tailored immunotherapy in various complement-mediated or autoimmune diseases.
Identifiants
pubmed: 31871840
doi: 10.7717/peerj.8218
pii: 8218
pmc: PMC6921979
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e8218Informations de copyright
© 2019 Winnicki et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Eur J Immunol. 2017 Mar;47(3):504-515
pubmed: 28083930
Semin Immunol. 2016 Jun;28(3):241-9
pubmed: 27402056
Expert Rev Clin Immunol. 2015;11(10):1109-19
pubmed: 26389851
PLoS Biol. 2019 Jul 22;17(7):e3000373
pubmed: 31329577
Nat Rev Immunol. 2008 Jan;8(1):48-58
pubmed: 18064050
Adv Exp Med Biol. 2013;735:247-55
pubmed: 23402032
Immunol Rev. 2016 Nov;274(1):33-58
pubmed: 27782325
Korean J Hematol. 2010 Dec;45(4):269-74
pubmed: 21253430
Eur J Clin Invest. 2015 Apr;45(4):423-40
pubmed: 25678219
Immunol Rev. 2001 Apr;180:35-48
pubmed: 11414361
Nat Rev Nephrol. 2018 Jan;14(1):26-47
pubmed: 29199277
Pediatr Nephrol. 2016 Mar;31(3):513-7
pubmed: 26572892
J Proteome Res. 2019 Jan 4;18(1):535-541
pubmed: 30351950
Immunol Lett. 1989 May;21(2):131-7
pubmed: 2527811
Blood. 2014 Mar 27;123(13):2094-101
pubmed: 24497537
World J Nephrol. 2015 May 6;4(2):169-84
pubmed: 25949931
Exp Hematol. 2014 Oct;42(10):857-61.e1
pubmed: 25034232
Immunol Res. 2007;37(3):161-75
pubmed: 17873401
Adv Exp Med Biol. 2014;772:229-62
pubmed: 24272362
Blood. 2010 Mar 18;115(11):2283-91
pubmed: 20068220
Mol Oral Microbiol. 2016 Feb;31(1):3-17
pubmed: 26332138
Sci Rep. 2016 Jun 27;6:28445
pubmed: 27345360
Mol Immunol. 2017 Sep;89:36-43
pubmed: 28576324
J Immunol. 2013 Apr 15;190(8):3839-47
pubmed: 23564578
J Biol Chem. 2007 Jan 26;282(4):2520-8
pubmed: 17132627
J Am Soc Nephrol. 2017 Jun;28(6):1753-1768
pubmed: 28073931
Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2570-8
pubmed: 27114510
Curr Transplant Rep. 2017;4(2):91-100
pubmed: 29214126
J Immunoassay Immunochem. 2016;37(1):43-54
pubmed: 25897558
J Am Soc Nephrol. 2015 Oct;26(10):2399-413
pubmed: 25644111
Kidney Int. 2015 Nov;88(5):967-73
pubmed: 26376132
Immunobiology. 2016 Jun;221(6):740-6
pubmed: 26101137
Semin Immunol. 2013 Feb;25(1):2-11
pubmed: 23694705
J Immunol. 1996 Mar 1;156(5):1989-96
pubmed: 8596054
Curr Opin Nephrol Hypertens. 2017 Mar;26(2):123-128
pubmed: 27977428
Nature. 2000 Aug 31;406(6799):998-1001
pubmed: 10984054
J Immunol. 2013 Jun 1;190(11):5712-21
pubmed: 23616575
Mol Immunol. 2017 Apr;84:2-9
pubmed: 28196665
Scand J Immunol. 1983 Mar;17(3):225-30
pubmed: 6402811
Glia. 2012 May;60(6):993-1003
pubmed: 22438044
BMJ Open. 2013 Nov 04;3(11):e003573
pubmed: 24189082
J Proteome Res. 2011 Dec 2;10(12):5354-62
pubmed: 22073976
Nat Rev Nephrol. 2013 Sep;9(9):495-6
pubmed: 23917793
Blood. 2015 Apr 9;125(15):2359-69
pubmed: 25608561
Nat Biotechnol. 2007 Nov;25(11):1256-64
pubmed: 17989688
J Biol Chem. 2009 Apr 17;284(16):10473-9
pubmed: 19196712
Clin J Am Soc Nephrol. 2012 May;7(5):748-56
pubmed: 22403278
Front Immunol. 2018 Aug 08;9:1851
pubmed: 30135690
Immunobiology. 2016 May;221(5):641-9
pubmed: 26847111
Lancet. 2015 Feb 26;385 Suppl 1:S57
pubmed: 26312879
Clin Exp Immunol. 1997 Jan;107(1):1-7
pubmed: 9010248
PeerJ. 2019 Oct 2;7:e7819
pubmed: 31592189
Immunobiology. 2016 Oct;221(10):1037-45
pubmed: 27371361
J Proteome Res. 2014 Aug 1;13(8):3679-84
pubmed: 24909410
FASEB J. 2017 May;31(5):2210-2219
pubmed: 28188176
Nephron. 2016;132(1):5-14
pubmed: 26695077
Glycoconj J. 2002 May-Jun;19(4-5):241-7
pubmed: 12975601
Blood. 2015 May 21;125(21):3253-62
pubmed: 25833956
Oncologist. 2008 Sep;13(9):993-1000
pubmed: 18784156
G3 (Bethesda). 2016 Aug 09;6(8):2467-78
pubmed: 27280787
J Immunol. 2007 Feb 1;178(3):1819-28
pubmed: 17237432
J Immunol. 2010 Mar 1;184(5):2686-92
pubmed: 20139276
Nat Biotechnol. 2007 Nov;25(11):1265-75
pubmed: 17989689
J Biol Chem. 1989 Sep 5;264(25):15109-14
pubmed: 2475494